UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-38938 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisd ...

Stoke Therapeutics, Inc. (STOK) came out with quarterly earnings of $1.90 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.57 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 613.51%. A quarter ago, it was expected that this company would post a loss of $0.51 per share when it actually produced a loss of $0.18, delivering a surprise of 64.71%.Over the last four quarters, ...

Financial Performance - Revenue recognized from the License and Collaboration Agreement with Biogen for the three months ended March 31, 2025 was $152.4 million, compared to no revenue for the same period in 2024[7] - Net income for the three months ended March 31, 2025 was $112.9 million, or $1.90 per diluted share, compared to a net loss of $26.4 million, or $0.57 per share for the same period in 2024[7] - Total revenue for the first quarter of 2025 was $158.6 million, compared to $4.2 million for the same period in 2024[16] Expenses - Research and development expenses for the three months ended March 31, 2025 were $32.7 million, compared to $22.4 million for the same period in 2024, including a one-time $8.2 million sublicense fee associated with the Biogen agreement[7] - General and administrative expenses for the three months ended March 31, 2025 were $14.7 million, compared to $10.2 million for the same period in 2024[7] Cash Position - As of March 31, 2025, the company had $380.3 million in cash, cash equivalents, and marketable securities, expected to fund operations beyond the second half of 2027 and into launch readiness projected for mid-2028[1] Collaboration with Biogen - The collaboration with Biogen includes an upfront payment of $165 million, with potential milestone payments of up to $385 million and tiered royalties on net sales[3] - The company retains exclusive rights for zorevunersen in the United States, Canada, and Mexico, while Biogen has exclusive commercialization rights for the rest of the world[3] Clinical Trials - The company plans to initiate the Phase 3 EMPEROR study in the second quarter of 2025, with an expected data readout in the second half of 2027[3] - The Phase 3 study will evaluate two loading doses of 70mg followed by two maintenance doses of 45mg over 52 weeks in children and adolescents with Dravet syndrome[4]

Wall Street expects a year-over-year increase in earnings on higher revenues when Stoke Therapeutics, Inc. (STOK) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the ...

Investors might want to bet on Stoke Therapeutics, Inc. (STOK) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sys ...

Stoke Therapeutics, Inc. (STOK) shares ended the last trading session 12% higher at $8.61. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.6% loss over the past four weeks.The sudden price rise can be attributed to growing investors' optimism related to the company’s progress with the development of its pipeline candidate zorevunersen for treating Dravet syndrome.This company is expected to post quarterly loss of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38938 Stoke Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation o ...

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.60 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 64.71%. A quarter ago, it was expected that this company would post a loss of $0.52 per share when it actually produced a loss of $0.47, delivering a surprise of 9.62%.Over the last four quarters, the company has ...

Financial Performance - The net loss for the year ended December 31, 2024 was $89.0 million, or $1.65 per share, compared to a net loss of $104.7 million, or $2.38 per share for 2023[7]. - The company reported a net loss of $10.5 million, or $0.18 per share, for the fourth quarter of 2024, compared to a net loss of $27.0 million, or $0.60 per share, for the same period in 2023[7]. - The net loss for the three months ended December 31, 2024, was $10,483 million, a decrease from a net loss of $26,958 million in the same period of 2023, indicating improved financial performance[17]. - Comprehensive loss for the year ended December 31, 2024, was $89,108 million, a decrease from $103,548 million in 2023, indicating a reduction in overall losses[17]. Revenue and Income - Revenue recognized from the License and Collaboration Agreement with Acadia Pharmaceuticals for the year ended December 31, 2024 was $36.6 million, a significant increase from $8.8 million in 2023[7]. - Revenue for the three months ended December 31, 2024, was $22,614 million, compared to $2,801 million for the same period in 2023, representing a significant increase[17]. - Total other income for the three months ended December 31, 2024, was $3,171 million, compared to $2,629 million in 2023, showing an increase of 20.7%[17]. Expenses - Research and development expenses for the year ended December 31, 2024 were $89.1 million, up from $82.2 million in 2023[7]. - General and administrative expenses for the year ended December 31, 2024 were $48.8 million, compared to $41.3 million in 2023[7]. - Total operating expenses for the three months ended December 31, 2024, were $36,268 million, up from $32,388 million in 2023, reflecting a year-over-year increase of 5.4%[17]. - Research and development expenses for the year ended December 31, 2024, totaled $89,133 million, an increase from $82,231 million in 2023, highlighting ongoing investment in innovation[17]. - General and administrative expenses for the year ended December 31, 2024, were $48,794 million, compared to $41,322 million in 2023, reflecting a year-over-year increase of 18.1%[17]. Cash and Funding - As of December 31, 2024, the company had $246.7 million in cash, cash equivalents, and marketable securities, which, along with the $165 million upfront payment from the Biogen collaboration, is expected to fund operations to mid-2028[1][7]. - The company is well-capitalized to advance through Phase 3 and prepare for launch readiness of zorevunersen[2]. Research and Development - The company plans to initiate the Phase 3 EMPEROR study of zorevunersen in the second quarter of 2025, following successful alignment with regulatory agencies[2][3]. - The FDA granted Breakthrough Therapy Designation for zorevunersen for the treatment of Dravet syndrome with a confirmed mutation in the SCN1A gene[4]. - The company retains exclusive rights for zorevunersen in the United States, Canada, and Mexico, while Biogen has exclusive commercialization rights for the rest of the world[3]. Share Information - The weighted average common shares outstanding for the three months ended December 31, 2024, increased to 57,029,296 from 44,958,894 in 2023, indicating a rise in share issuance[17]. Marketable Securities - The company reported an unrealized loss on marketable securities of $(317) million for the three months ended December 31, 2024, compared to a gain of $122 million in the same period of 2023[17].

Core Viewpoint - Stoke Therapeutics, Inc. (STOK) is anticipated to report a year-over-year increase in earnings driven by higher revenues, which could significantly influence its near-term stock price depending on the actual results compared to estimates [1][2]. Earnings Expectations - The upcoming earnings report is expected to show a quarterly loss of $0.51 per share, reflecting a year-over-year improvement of +15% [3]. - Revenues are projected to reach $3.88 million, representing a 38.6% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.85% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Zacks Earnings ESP for Stoke Therapeutics is +1.48%, suggesting a positive outlook for the company's earnings prospects [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [8]. - Stoke Therapeutics has a Zacks Rank of 3, which, along with the positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Stoke Therapeutics was expected to post a loss of $0.52 per share but actually reported a loss of $0.47, resulting in a surprise of +9.62% [12]. - The company has successfully beaten consensus EPS estimates in the last four quarters [13]. Conclusion - While Stoke Therapeutics is positioned as a compelling earnings-beat candidate, other factors should also be considered when evaluating the stock ahead of its earnings release [16].